The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information:

Study Name on (link is external)
A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
Study Drug VX-659 in triple combination with tezacaftor and ivacaftor 
Type of Study Drug CFTR modulator
Study Title A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)
Study Phase 3
Study Sponsor Vertex

Link on (link is external)

Participating ECFS-CTN sites Please contact for most recent sitelist
Age 12 years and older